Phase 2 updated results for zanidatamab in HER2-positive mGEA included a confirmed objective response rate (cORR) of 84%, duration of response (DoR) of 18.7 months, median progression-free survival (mPFS) of 15.2 months and a Kaplan-Meier–estimated overall survival (OS) of 59% at 30 months DUBLIN, Sept. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced updated data, including median progression-free survival (mPFS) and overall survival (OS) findings, from the Phase 2 trial of ...

New and updated data from an ongoing Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) DUBLIN, Sept. 9, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company, along with its partners, will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17, 2024, in ...

Data from eight abstracts to be presented, including results of the BECOME (BEhavior, COgnition and More with Epidyolex®) Caregiver Survey on the real-world outcomes of Epidyolex® (cannabidiol) treatment on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) DUBLIN, Sept. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present eight abstracts at the 15th European Epilepsy Congress (EEC), including a subgroup analysis of the BECOME (BEhav ...

DUBLIN, Sept. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced the pricing of $850 million aggregate principal amount of 3.125% exchangeable senior notes due 2030 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Issuer also granted the initial purc ...

文章核心观点 - 公司宣布在日本进行的一项针对癫痫相关症状的3期临床试验未达到预设的主要疗效终点,但观察到了一些数字上的改善[1] - 公司表示对癫痫药物Epidyolex的整体临床数据充满信心,并计划与日本监管机构就提交新药申请进行沟通[2] - 公司认识到日本患有罕见癫痫的患者存在巨大的未满足医疗需求,并感谢参与试验的研究人员、患者及照顾者[2] 试验概况 - 这是一项开放标签、单臂的3期临床试验,评估了大麻二酚口服溶液(商品名Epidiolex/Epidyolex)作为治疗LGS、DS或TSC相关癫痫发作的辅助治疗的安全性和有效性[3] - 该试验的主要疗效终点是治疗期(最长16周)内与基线相比,相关癫痫发作频率的百分比变化[3] - 该试验正在持续进行,以收集日本儿童和成人患者的疗效和安全性数据[3] 药物信息 - 大麻二酚口服溶液是一种处方植物源性大麻类药物,已获美国FDA和欧洲EMA批准用于治疗LGS、DS或TSC相关癫痫发作[4] - 在美国,大麻二酚(商品名Epidiolex)适用于1岁及以上患者;在欧盟,Epidyolex适用于2岁及以上患者,作为辅助治疗用于LGS、DS或TSC相关癫痫[4] 公司概况 - 爵士制药是一家总部位于爱尔兰的全球生物制药公司,致力于为患有严重疾病的患者开发创新药物[5] - 公司拥有多种上市药物,包括治疗睡眠障碍和癫痫的领先疗法,以及不断增长的肿瘤治疗药物组合[5] - 公司以以患者为中心和科学驱动的方法推动创新研发,在肿瘤学和神经科学领域拥有丰富的管线[5]

DUBLIN, Aug. 21, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences:Wells Fargo Healthcare Conference on Wednesday, September 4, 2024Fireside chat at 7:15 a.m. PT / 10:15 a.m. ET / 3:15 p.m. ISTBank of America Global Healthcare Conference on Wednesday, September 18, 2024Fireside chat at 7:55 a.m. PT / 10:55 a.m. ET / 3:55 p.m. ISTAudio webcasts of the fireside chats will be available via the Investors se ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style S ...

Shares of Jazz Pharmaceuticals (JAZZ) have gained 10.8% over the past four weeks to close the last trading session at $111.60, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $174.83 indicates a potential upside of 56.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.43. While the lowest estimate i ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use fundamental analysis and traditional va ...

Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $5.30 per share in second-quarter 2024, beating the Zacks Consensus Estimate of $4.68. Earnings rose 18% year over year.Total revenues in the reported quarter rose 7% year over year to $1.02 billion. Sales of Xywav, Epidiolex and Rylaze drove the upside. The reported figure beat the Zacks Consensus Estimate of $1.0 billion.Quarter in DetailNet product sales rose 2% year over year at $964.1 million. The reported figure beat the Zacks Consensus Estimat ...